New research out of VCU Massey Comprehensive Cancer Center—published in Brain, Behavior and Immunity—is the first to suggest that a tumor-driving gene known as AEG-1 actively regulates the inflammation responsible for causing chemotherapy-induced peripheral neuropathy (CIPN), a common and painful side effect of cancer treatment. Eliminating the function of this gene using targeted therapies could become a critical strategy for managing a debilitating side effect experienced by many cancer patients.

Research has shown that ferroptosis can overcome chemotherapy resistance induced by apoptosis, making the combination of chemotherapy and ferroptosis a very promising strategy for cancer treatment. However, the high levels of glutathione in the tumor environment and insufficient intracellular iron content limit the anticancer effects mediated by ferroptosis. Recently, a study published in Nano Research utilized the tumor environment to achieve a "multi-machine integrated" combined strategy, enhancing the therapeutic effects of chemotherapy and ferroptosis. The study was published in Nano Research with the DOI of 10.26599/NR.2025.94907298.

The National Comprehensive Cancer Network^® (NCCN^®) announces 2025 awardees who go above and beyond to define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.

Researchers at the Max Planck Institute for Biology of Ageing have discovered that the combination of the two cancer drugs Rapamycin and Trametinib significantly extends the lifespan of mice. This therapy shows greater effects than the individual drugs and offers not only a longer lifespan, but also health benefits in old age. The results suggest that this drug combination could be a promising strategy for combating age-related diseases and promoting longevity.

HOUSTON, MAY 28, 2025 ― Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), following treatment with the KRAS targeted therapy sotorasib.

Researchers from the University of Science and Technology of China report the first near-atomic-resolution structure of the human ATR–ATRIP complex bound to clinical inhibitors, providing critical insights into ATR regulation and inhibition.